PH & HHT – Signs, Symptoms
& Disease Management (Recorded)
PH and HHT: Signs, Symptoms & Disease Management Join PHA and Cure HHT for the PHA Live webinar “PH and HHT: Signs, Symptoms and Disease Management” at 7:30 p.m. EDT,…
Read More
Register Now! Patient & Physician Conference
Patient & Physician Conference Virtual | April 29 – May 7, 2022 The Cure HHT Academy is pleased to present its 1st Virtual Patient/Physician Conference this spring. The conference is…
Read More
14th HHT Scientific Conference: Abstract Submission Deadline Extended!
The HHT International Scientific Conference is hosted and sponsored by Cure HHT. The Conference Organizing Committee invites authors to submit abstracts to be considered for inclusion in the 14th HHT International…
Read More
Federal Funding Secured for U.S. Centers of Excellence
A message from Cure HHT Executive Director, Marianne Clancy It is with tearful joyfulness that I share this truly momentous news with you: Our HHT Center of Excellence (CoE) funding…
Read More
Cure HHT Scientific Newsletter
Twice a year, Cure HHT collaborates with its global research and medical advisory board to publish HHT Frontlines – a scientific newsletter aimed at centralizing, summarizing, and sharing the most…
Read More
CHRN: Creating a Roadmap for the Future
A Message from Marianne Clancy, Cure HHT Executive Director Transformational. That’s the word that keeps coming to mind since returning from Boston, the site of the 1st Cure HHT Research…
Read More
Cure HHT Leads Global Breakthrough in Bleeding Standards, Paving the Way for Future HHT Therapies
International Consensus Report Published in the American Journal of Hematology Aims to Transform HHT Research, Treatment, and Clinical Trials
Read More
A History of Pazopanib
There are no FDA-approved therapeutics for the treatment of HHT. Cure HHT sought to change that. In many ways,…
Read More
This Landmark HHT Study Could Shift National Attention
We’re excited to share some truly important news for the HHT community. A major new study done in collaboration…
Read More
Volunteers Needed! Join Cure HHT on Capitol Hill
We are calling upon volunteers to Join us in Washington, DC, for HHT Hill Day and be the voice…
Read More
Cure HHT’s 2024 Impact Report
2024: A Year of Significant Transformation and Progress Every year is a different chapter in our story – each…
Read More
Press Release: Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of HHT
Diagonal Therapeutics — who has raised $128 million in Series A funding to support their sole project, a curative…
Read More
Press Release: Vaderis Receives FDA Fast Track Designation for Treatment of HHT
The below press release was issued Monday, Nov. 18 by Vaderis Therapeutic, and is substantial news for our community. Cure HHT…
Read More
A Monumental $128 Million Step Forward for HHT Research
Today is a monumental day for HHT. The new biotechnology company, Diagonal Therapeutics, officially launched and we wanted to share more about why this is news you simply can’t miss!
In short, Diagonal’s lead program is focused on developing an innovative treatment not just to alleviate the symptoms of HHT – but using antibodies to reverse the formation of vascular malformations altogether. That’s right, there is now a biotechnology company, backed by $128 million in Series A financing, focused entirely on a curative HHT therapy.
For months, Cure HHT has been collaborating with Diagonal’s management team to help make this day a reality. We have connected them to leading HHT scientists to help them further develop their program, and have spent countless hours meeting with venture capital firms to educate them on the burden of this disease and help Diagonal secure funding to launch.
Read More